← 返回

白细胞介素-15 与固有效应细胞作为异基因造血干细胞移植结局的预测因素

英文原题:Interleukin-15 and innate effector cells as predictors of outcome in allogeneic hematopoietic cell transplantation.

查看英文原题

Interleukin-15 and innate effector cells as predictors of outcome in allogeneic hematopoietic cell transplantation.

PubMed 2026/02/02(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

这些发现可能提示,NK 细胞和 T 细胞的早期免疫重建受 HCT 后 IL-15 生物利用度的影响,并且 IL-15 可能在这些固有效应细胞的活性中发挥机制性作用。

中文摘要

**引言:**免疫重建是造血细胞移植(HCT)成功的关键指标,涉及多种细胞类型及细胞因子构成的微环境。已知自然杀伤(NK)细胞和T细胞在HCT后较早重建,并可能介导移植物抗白血病(GVL)效应而不伴随移植物抗宿主病(GVHD)。白细胞介素15(IL-15)和IL-7是重要稳态细胞因子,可作用于T细胞和NK细胞,因此在HCT情境中特别值得关注。**方法:**本前瞻性研究纳入单中心105例接受异基因HCT的患者,纵向测量固定时间点的IL-15、IL-7、T细胞和NK细胞(包括活化亚型),并分析其与临床结局的关联。**结果:**移植早期IL-15浓度较高与总生存期降低、无复发生存期降低及急性GVHD发生过多显著相关。

此外,IL-15与移植早期NK细胞及T细胞(包括活化亚型)呈显著负相关,并与较晚时间点的常规T细胞负相关。IL-7不仅与常规T细胞显著负相关,也与移植早期T细胞负相关。**讨论:**结果提示,HCT后IL-15生物可利用度可能影响NK细胞和T细胞的早期免疫重建;IL-15或会对这些先天效应细胞的活性产生机制性影响。NK细胞和T细胞目前正在多个有前景的治疗领域中接受研究,IL-15或可为相关应用带来潜在获益。

展开英文摘要原文

In this prospective study, we investigated associations between IL-15 and IL-7, NK cells and T cells, including activated subtypes, and clinical outcomes. We included 105 patients undergoing allogeneic HCT at a single-center institution. IL-15, IL-7, and extended T and NK cell phenotyping were measured longitudinally at fixed time points following HCT.

We found high IL-15 concentrations early post-transplant to be significantly associated with reduced overall survival, reduced relapse-free survival, and excess acute GVHD. Furthermore, IL-15 showed significant inverse correlations with NK cells and T cells, including activated subtypes early after HCT, and with conventional T cells at later time points. IL-7 was significantly inversely correlated not only with conventional T cells but also with T cells early after HCT. DISCUSSION: These findings may suggest that early immune reconstitution of NK cells and T cells is influenced by the bioavailability of IL-15 after HCT and that IL-15 could have a mechanistic effect in the activity of these innate effector cells. NK cells and T cells are currently being investigated in several promising treatment settings, and IL-15 here may offer a potential benefit.

论文信息

作者
Warny M、Ostrowski SR、Petersen SL、Friis LS、Kornblit BT、Andersen NS、Schjødt I、Larsen MH
第一作者单位
Department of Hematology, Danish Red Blood Cell Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.Denmark
通讯作者单位
Department of Clinical Immunology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.Denmark
期刊
Frontiers in immunology2025
原文标识
PubMed 41704538 · DOI 10.3389/fimmu.2025.1649313